JW (Cayman) Therapeutics Co. Ltd (02126.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 2.23

From 52W high−57.53%

Volume3.41M

Market capHKD 914.73M

P/E (TTM)—

P/S (TTM)2.7x

Div yield—

Key dataSep 18, 2026

Open

HKD 2.23

From 52W high

−57.53%

Volume

3.41M

Market cap

HKD 914.73M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.4x

P/E (TTM)

—

RSI (14)

63.1

MomentumView details →

1D Return

+0.46%

YTD Return

−12.35%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.4x

EV/Sales

2.3x

P/S (TTM)

2.7x

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

39.80%

Net Margin

−116.75%

EBITDA Margin

−67.34%

ROE (TTM)

−73.78%

ROA (TTM)

−40.06%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+60.80%

EPS YoY

+46.31%

FCF YoY

+61.30%

Revenue CAGR 3Y

+23.78%

EPS CAGR 3Y

+9.09%

EBITDA YoY

+24.88%

MomentumView details →

1D Return

+0.46%

YTD Return

−12.35%

1Y Return

−55.82%

RSI (14)

63.1

vs 50D SMA

+18.08%

vs 200D SMA

+0.74%

Capital & dividendView details →

Debt/Equity

0.56x

Current Ratio

1.43x

Quick Ratio

1.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.14

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

463.57M

Net Income (TTM)

−951.33M

Op. CF (TTM)

—

Next earningsApr 1, 2027 →

Latest newsMore news →

JW Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB111.4 million, up 4.7% year-on-year, and net loss narrowed to RMB50.43 million from RMB267.3 million in the prior-year period.24d ago

Similar companies

Lexicon Pharmaceuticals, Inc.LXRX CANbridge Pharmaceuticals Inc.01228.HK Cybin Inc. Common StockHELP Sana Biotechnology, Inc.SANA Immix Biopharma, Inc.IMMX Inventiva S.A.IVA Find similar companies →

Latest newsMore news →

JW Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB111.4 million, up 4.7% year-on-year, and net loss narrowed to RMB50.43 million from RMB267.3 million in the prior-year period.24d ago